TY - JOUR
T1 - Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder
AU - Lipstein, Noa
AU - Verhoeven-Duif, Nanda M.
AU - Michelassi, Francesco E.
AU - Calloway, Nathaniel
AU - Van Hasselt, Peter M.
AU - Pienkowska, Katarzyna
AU - Van Haaften, Gijs
AU - Van Haelst, Mieke M.
AU - van Empelen, R.
AU - Cuppen, Inge
AU - Van Teeseling, Heleen C.
AU - Evelein, Annemieke M V
AU - Vorstman, Jacob A.
AU - Thoms, Sven
AU - Jahn, Olaf
AU - Duran, KJ
AU - Monroe, Glen R.
AU - Ryan, Timothy A.
AU - Taschenberger, Holger
AU - Dittman, Jeremy S.
AU - Rhee, Jeong Seop
AU - Visser, Gepke
AU - Jans, Judith J.
AU - Brose, Nils
N1 - Funding Information:
Acknowledgments We are extremely grateful for the contribution of the patient's family to this study. We thank Christian Rosenmund (Berlin, Germany) for the gift of a viral expression vector; Fritz Benseler, the AGCT laboratory, Anja Günther, and Astrid Zeuch (Göttingen, Germany) for excellent technical support; Edwin Cuppen for facilitating WES; Marjolein van Susante and Karlijn Daniels-Steggehuis for psychological assessments; and the staff of the Max Planck Institute of Experimental Medicine Animal Facility (Göttingen, Germany) for mouse husbandry. This work was supported by the Max Planck Society (Munich, Germany; to NB), the European Research Council (Brussels, Belgium; ERC-ADG SYNPRIME to NB), the German Research Foundation (Bonn, Germany; CNMPB FZT103 to NB), and the NIH (NIH/NIGMS R01GM095674 to JSD, T32GM007739 to FEM).
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Munc13 proteins are essential regulators of neurotransmitter release at nerve cell synapses. They mediate the priming step that renders synaptic vesicles fusion-competent, and their genetic elimination causes a complete block of synaptic transmission. Here we have described a patient displaying a disorder characterized by a dyskinetic movement disorder, developmental delay, and autism. Using whole-exome sequencing, we have shown that this condition is associated with a rare, de novo Pro814Leu variant in the major human Munc13 paralog UNC13A (also known as Munc13-1). Electrophysiological studies in murine neuronal cultures and functional analyses in Caenorhabditis elegans revealed that the UNC13A variant causes a distinct dominant gain of function that is characterized by increased fusion propensity of synaptic vesicles, which leads to increased initial synaptic vesicle release probability and abnormal short-term synaptic plasticity. Our study underscores the critical importance of fine-tuned presynaptic control in normal brain function. Further, it adds the neuronal Munc13 proteins and the synaptic vesicle priming process that they control to the known etiological mechanisms of psychiatric and neurological synaptopathies.
AB - Munc13 proteins are essential regulators of neurotransmitter release at nerve cell synapses. They mediate the priming step that renders synaptic vesicles fusion-competent, and their genetic elimination causes a complete block of synaptic transmission. Here we have described a patient displaying a disorder characterized by a dyskinetic movement disorder, developmental delay, and autism. Using whole-exome sequencing, we have shown that this condition is associated with a rare, de novo Pro814Leu variant in the major human Munc13 paralog UNC13A (also known as Munc13-1). Electrophysiological studies in murine neuronal cultures and functional analyses in Caenorhabditis elegans revealed that the UNC13A variant causes a distinct dominant gain of function that is characterized by increased fusion propensity of synaptic vesicles, which leads to increased initial synaptic vesicle release probability and abnormal short-term synaptic plasticity. Our study underscores the critical importance of fine-tuned presynaptic control in normal brain function. Further, it adds the neuronal Munc13 proteins and the synaptic vesicle priming process that they control to the known etiological mechanisms of psychiatric and neurological synaptopathies.
UR - http://www.scopus.com/inward/record.url?scp=85015969576&partnerID=8YFLogxK
U2 - 10.1172/JCI90259
DO - 10.1172/JCI90259
M3 - Article
C2 - 28192369
SN - 0021-9738
VL - 127
SP - 1005
EP - 1018
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 3
ER -